OBJECTIVE: Heart failure is an important cause of death in patients with rheumatoid arthritis (RA). Evidence suggests that immune mechanisms contribute to myocardial injury and fibrosis, leading to left ventricular diastolic dysfunction (LVDD). The purpose of this study was to identify a signature of LVDD in patients with RA by analyzing the responsiveness of the innate and adaptive immune systems to stimulation ex vivo. METHODS: RA patients (n=212) enrolled prospectively in a population-based cohort underwent echocardiography, and LV function was classified as normal, mild LVDD, or moderate-to-severe LVDD. The release of 17 cytokines by blood mononuclear cells in response to stimulation with a panel of 7 stimuli or in media alone was analyzed using multiplex immunoassays. Logistic regression models were used to test for associations between a multicytokine immune response score and LVDD, after adjusting for clinical covariates. RESULTS: An 11-cytokine profile effectively differentiated patients with moderate-to-severe LVDD from those with normal LV function. An immune response score (range 0-100) was strongly associated with moderate-to-severe LVDD (odds ratio per 10 units 1.5 [95% confidence interval 1.2-2.1]) after adjusting for serum interleukin-6 levels, brain natriuretic peptide values, and glucocorticoid use, as well as other RA characteristics and LVDD risk factors. CONCLUSION: The major finding of this study was that aberrant systemic immune responsiveness is associated with advanced myocardial dysfunction in patients with RA. The unique information added by the immune response score concerning the likelihood of LVDD warrants future longitudinal studies of its value in predicting future deterioration in myocardial function.
OBJECTIVE:Heart failure is an important cause of death in patients with rheumatoid arthritis (RA). Evidence suggests that immune mechanisms contribute to myocardial injury and fibrosis, leading to left ventricular diastolic dysfunction (LVDD). The purpose of this study was to identify a signature of LVDD in patients with RA by analyzing the responsiveness of the innate and adaptive immune systems to stimulation ex vivo. METHODS:RApatients (n=212) enrolled prospectively in a population-based cohort underwent echocardiography, and LV function was classified as normal, mild LVDD, or moderate-to-severe LVDD. The release of 17 cytokines by blood mononuclear cells in response to stimulation with a panel of 7 stimuli or in media alone was analyzed using multiplex immunoassays. Logistic regression models were used to test for associations between a multicytokine immune response score and LVDD, after adjusting for clinical covariates. RESULTS: An 11-cytokine profile effectively differentiated patients with moderate-to-severe LVDD from those with normal LV function. An immune response score (range 0-100) was strongly associated with moderate-to-severe LVDD (odds ratio per 10 units 1.5 [95% confidence interval 1.2-2.1]) after adjusting for serum interleukin-6 levels, brain natriuretic peptide values, and glucocorticoid use, as well as other RA characteristics and LVDD risk factors. CONCLUSION: The major finding of this study was that aberrant systemic immune responsiveness is associated with advanced myocardial dysfunction in patients with RA. The unique information added by the immune response score concerning the likelihood of LVDD warrants future longitudinal studies of its value in predicting future deterioration in myocardial function.
Authors: M Di Franco; M Paradiso; A Mammarella; V Paoletti; G Labbadia; L Coppotelli; E Taccari; A Musca Journal: Ann Rheum Dis Date: 2000-03 Impact factor: 19.103
Authors: Cynthia S Crowson; Elena Myasoedova; John M Davis; Veronique L Roger; Barry L Karon; Daniel Borgeson; Richard J Rodeheffer; Terry M Therneau; Sherine E Gabriel Journal: Arthritis Care Res (Hoboken) Date: 2011-05 Impact factor: 4.794
Authors: John M Davis; Keith L Knutson; Michael A Strausbauch; Cynthia S Crowson; Terry M Therneau; Peter J Wettstein; Eric L Matteson; Sherine E Gabriel Journal: J Immunol Date: 2010-05-21 Impact factor: 5.422
Authors: Yi Zhang; Michel E Safar; Pierre Iaria; Davide Agnoletti; Athanase D Protogerou; Jacques Blacher Journal: Am Heart J Date: 2010-09 Impact factor: 4.749
Authors: Paulo J Nicola; Hilal Maradit-Kremers; Véronique L Roger; Steven J Jacobsen; Cynthia S Crowson; Karla V Ballman; Sherine E Gabriel Journal: Arthritis Rheum Date: 2005-02
Authors: Megan L Krause; John M Davis; Keith L Knutson; Michael A Strausbauch; Michael A Strausbach; Cynthia S Crowson; Terry M Therneau; Peter J Wettstein; Eric L Matteson; Sherine E Gabriel Journal: Clin Immunol Date: 2011-05-30 Impact factor: 3.969
Authors: John M Davis; Keith L Knutson; John A Skinner; Michael A Strausbauch; Cynthia S Crowson; Terry M Therneau; Peter J Wettstein; Eric L Matteson; Sherine E Gabriel Journal: Arthritis Res Ther Date: 2012-01-31 Impact factor: 5.156
Authors: John M Davis; Keith L Knutson; Michael A Strausbauch; Abigail B Green; Cynthia S Crowson; Terry M Therneau; Eric L Matteson; Sherine E Gabriel Journal: Arthritis Res Ther Date: 2013 Impact factor: 5.156